CHF 40.00
In stock
AG-CR1-3730-G0011 gCHF 40.00
AG-CR1-3730-G0055 gCHF 120.00
More Information
Product Details
Synonyms MK-208; YM-11170; Pepcid; N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
Product Type Chemical


MW 337.5
CAS 76824-35-6
RTECS UA2300000
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (30mg/ml) or DMF (30mg/ml).
Identity Determined by 1H-NMR.
Smiles N/C(N)=N/C1=NC(CSCC/C(N)=N/S(=O)(N)=O)=CS1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Famotidine is a histamine H2 receptor antagonist. It is selective for H2 over H1 and muscarinic receptors (Kis = 4 and 28 µM, respectively, in bovine cerebral cortex).

  • Famotidine blocks the action of histamine in the parietal cells, ultimately blocking acid secretion in the stomach. It inhibits histamine-induced acid secretion in isolated canine parietal cells (IC50 = 0.6µM) and suppresses histamine-induced gastric acid secretion in dogs when administered orally and in anesthetized rats when administered intraduodenally (ID50s = 10 and 400µg/kg, respectively).

  • Famotidine is used to treat ulcers, gastroesophageal reflux disease (GERD) and heartburn and it decreases the risk of gastrointestinal toxicity associated with non-steroidal anti-inflammatory drugs (NSAIDs).

  • Potential inhibitor of the viral enzyme papain-like protease (PLpro), important for SARS-CoV-2 replication and being tested in COVID-19 clinical trials.

Product References
  1. Pharmacokinetics of famotidine, a new H2-receptor antagonist, in relation to renal function: T. Takabatake, et al.; Eur. J. Clin. Pharmacol. 28, 327 (1985)
  2. Antimuscarinic effects of antihistamines: Quantitative evaluation by receptor-binding assay: N. Kubo, et al.; Jap. J. Pharmacol 43, 277 (1987)
  3. Famotidine. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in peptic ulcer disease and other allied diseases: H.D. Langtry, et al.; Drugs 38, 551 (1989) (Review)
  4. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs: H. Nagaya, et al.; Jap. J. Pharmacol. 55, 425 (1991)
  5. Clinical pharmacokinetics of famotidine: H. Echizen & T. Ishizaki; Clin. Pharmacokinet. 21, 178 (1991) (Review)
  6. Famotidine, the new antiulcero-genic agent, a potent ligand for metal ions: H. Kozlowski, et al.; J. Inorg. Biochem. 48, 233 (1992)
  7. Famotidine in gastroesophageal reflux disease (GERD): I.C. Wesdorp; Hepatogastroenterology 1, 24 (1992) (Review)
  8. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods: C. Wu, et al.; Acta Pharm. Sin. B. (Epub ahea of print) (2020) 
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.